Seventeen serious cases have been reported in France due to the improper use of medications originally designed to treat obesity and diabetes for weight loss purposes. The National Agency for the Safety of Medicines and Health Products (ANSM) released a report on October 7, highlighting the "persistence of dangerous misuse" of these drugs, which have been linked to "serious complications." Between February 2025 and January 2026, the agency received 36 reports of adverse effects from the misuse of anti-obesity medications known as aGLP-1. Of these, 17 were classified as serious. According to the ANSM, the adverse effects associated with the misuse of aGLP-1 medications primarily affect young people. In two out of every three cases, the medication was obtained through unofficial means, such as the internet, friends or family, or abroad. Additionally, in 90% of the cases, the doses used were either too high or increased too quickly compared to the recommended guidelines. Among the 17 serious cases, five involved acute pancreatitis, a known side effect of these medications that can also occur in patients who have been prescribed the treatment properly. The most commonly reported adverse effects, which are listed in the drug's leaflets, include gastrointestinal issues that may require hospitalization, as well as the serious risk of pancreatitis. From February 2025 to January 2026, more than 840,000 French patients received treatment with aGLP-1 medications. Four different medications, including the well-known Ozempic, are used to treat type 2 diabetes, while three others, including Wegovy, are approved for weight control and the management of obesity. During this time, 2,801 cases of adverse effects were reported, including 515 serious cases. The ANSM is urging for greater monitoring and systematic prevention of these adverse effects. Two cases of pancreatitis were reported as "possibly responsible for deaths," and two other deaths were "could be related" to an increased risk of lactic acidosis in some diabetic patients, according to the agency. Other investigations are ongoing to determine whether certain adverse effects observed during treatment are connected to the use of anti-obesity medications. This includes possible risks such as reduced effectiveness of contraceptives, eye damage, erectile dysfunction, or damage to the brain's blood vessels.